New 'In-Body' CAR-T therapy takes aim at Hard-to-Treat lymphoma
NCT ID NCT07620314
First seen Jun 06, 2026 · Last updated Jun 22, 2026 · Updated 3 times
Summary
This early study tests a new treatment called KSVCBD for people with a type of blood cancer called B-cell non-Hodgkin's lymphoma that has come back or not responded to other treatments. KSVCBD is a special therapy that works inside the body to help immune cells attack cancer cells. The trial will include 9 participants and will focus on safety and the right dose, while also checking if the cancer shrinks.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-HODGKIN'S LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Biotherapeutic Department of Chinese PLA General Hospital
RECRUITINGBeijing, Beijing Municipality, 100853, China
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
KSVCBD injection (a type of CAR-T cell therapy that targets CD19 and BCMA proteins on cancer cells)
What this could lead to
If successful, this could point toward a more convenient CAR-T therapy that is given directly in the body, potentially improving treatment for certain lymphomas.
What could go wrong
This is a very early, small Phase 1 trial with only 9 participants, so safety and effectiveness are not yet proven. There are risks of serious side effects like cytokine release syndrome and nerve toxicity.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.